Clinical Trial Update: The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating de-novo use of eculizumab in presensitized cardiac transplant patients completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection in Cardiac Transplantation
• Cardiac Allograft Rejection
• Cardiac Allograft Vasculopathy
• Heart Transplant Rejection
• Hyperacute Rejection of Cardiac Transplant
• Left Ventricular Dysfunction in Heart Transplant Recipients

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant | Phase 3 | Status: COMPLETED | Results posted: 2021-05-03